You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

May 15, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Pharma and payers not aligned, says survey

A new survey has found that pharmaceutical companies and payers are not seeing eye to eye. » Full article

Teriflunomide delays onset of disease in those with early signs of MS

There is value in treating multiple sclerosis (MS) early, according to results from a study presented during the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia.
» Full article

Continuing Education

MTM essentials for hypertension—Part 2: Drug therapy considerations

This month's article is the fourth in a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to discuss place in therapy of drug classes used to treat hypertension and review drug considerations of prescription antihypertensive mediations and herbal supplements that are relevant to medication therapy management of hypertension.

To read and print the article with TEST QUESTIONS, click here.
To proceed to the online exams and earn up to 2 CPE credits, click here to log in.


Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net. This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

 

Related Articles

Prescription trend remains modest

Low vitamin D levels can predict multiple sclerosis progression

RESOURCES

Latest Clinical News

EDITOR'S PICK

Drugs in Context: Farxiga (dapagliflozin)

Antidiabetic drugs are considered to be first-line treatment options for individuals with type 1 and type 2 diabetes mellitus. It is estimated that type 2 diabetes affects about 24 million persons in the United States. Over time high blood levels can lead to complications such as heart disease, kidney damage, or blindness. » Full article

Powered by Modern Medicine Advanstar Medical Communications Group